Tscan Therapeutics, Inc. · NASDAQ:TCRX
Tscan Therapeutics — ACR Convergence 2025
14 slides from Tscan Therapeutics's conference presentation, October 2025
Slide 1: TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis
0888: TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis ACR Convergence 2025
Slide 2: Disclaimers and forward-looking statements
Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking TScan’s plans relating to developing and commercializing its TCR-T therapy statements within the meaning of the Private Securities Litigation Reform Act of product candidates, if appr
Slide 3: TScan is a fully integrated, clinical-stage, TCR-T cell therapy company
TScan is a fully integrated, clinical-stage, TCR-T cell therapy company Proprietary discovery platform Clinical-phase oncology pipeline T-cell receptor (TCR) Clinical-phase programs in heme Rapid discovery of targets and TCRs and solid tumor malignancies In-house GMP manufacturing Broad therapeutic
Slide 4: Nine TCR-T candidates in clinical development, with new TCR-Ts advancing
Nine TCR-T candidates in clinical development, with new TCR-Ts advancing Indications Programs (target) HLA type Discovery Lead optimization IND-enabling Phase 1 Phase 2/3 TSC-100 HLA-A*02:01 (HA-1) AML, TSC-101 HLA-A*02:01 HEMATOLOGIC MDS, (HA-2) MALIGNANCIES ALL HLA-A*03:01 TSC-102 HLA-A*01:01 (CD4
Slide 5: TargetScan enables the discovery of autoreactive T cell receptor targets
TargetScan enables the discovery of autoreactive T cell receptor targets T cells expressing Genome-wide library TCR of interest of target cells Protein fragments are processed naturally and Peptide-MHC span every annotated human protein Protein 1 Protein 2 Protein N C fragment Overlapping library fr
Slide 6: TScan has established a broad network of tissue sample providers for autoimmune diseases
TScan has established a broad network of tissue sample providers for various autoimmune diseases and has initiated target discovery in focused indications Relevant Specialties Discovery Focus Ulcerative Gastroenterologists Colitis MHC Class II Screening Focus (See Poster #0997) Autoimmune Systemic P
Slide 7: Initial target discovery is focused on ankylosing spondylitis and birdshot uveitis
Initial target discovery is focused on ankylosing spondylitis and birdshot uveitis because of strong associations with HLA Ankylosing Spondylitis (AS) Birdshot Uveitis (BU) • Chronic inflammatory disease- • Loss of peripheral vision in causing back pain and spinal advanced cases, floaters, blurred s
Slide 8: TCRs were sourced containing a well-characterized TCR sequence motif associated with AS pathology
TCRs were sourced containing a well-characterized TCR sequence motif associated with AS pathology TCR Selection Tissue Sample • Clonally expanded CD8 + T cells carrying the TRBV9+ gene segment are enriched in blood, joints and eyes of AS patients1,2, 3 T cell FACS AS-associated TCR Motif2 TCRalpha C
Slide 9: TargetScan identified novel targets recognized by TCRs with AS-associated sequence motif
TargetScan identified novel targets recognized by TCRs with AS-associated sequence motif Internally sourced TCRs Published TCRs TargetScan screens identified 38 targets that were not previously described 9
Slide 10: Identified targets are shared across patients and have biologic links to AS pathology
Identified targets are shared across patients and have biologic links to AS pathology Reactivity to full-length protein Reactivity to minimal epitopes Reactivity across patients Internal Targets AS-T007 50% 60 AS-T021 Internal TCR AS-T027 Patient #1 TCR 1 40 Published Targets 20 YEIH TCR 2 HELQ T ce
Slide 11: TCRs from BU inflamed eye samples were screened using TargetScan
TCRs from BU inflamed eye samples were screened using TargetScan Single Cell TargetScan Tissue Sample T cell FACS TCR Selection Sequencing Screen Few TCR clones are Patient #1 Patient #2 Patient #3 obtained from eye (Posterior chamber) (Anterior chamber) (Posterior chamber) fluid samples TCRs are pr
Slide 12: TargetScan identified a family of genes recognized by TCRs from inflamed BU eye tissue
TargetScan identified a family of genes recognized by TCRs from inflamed BU eye tissue Normal Retina BU Retina Macular retina Common Gene Family Peripheral retina Peripheral retina adjacent to vasculature are more commonly affected in BU Common Gene Family 200 Tissue Expression Expression (TPM) 150
Slide 13: Conclusions
Conclusions • TScan’s proprietary platform, TargetScan, enables the unbiased identification of novel T cell autoantigens for both MHC Class I and Class II presented T cell antigens • TScan has established a broad network of tissue sample providers for various autoimmune diseases, and has initiated t
Slide 14: Acknowledgements
Acknowledgements Cloning and Virus Production Clinical and Lab Ops TScan Therapeutics Livio Dukaj Shrikanta Chattopadhyay Shoshana Bloom Laurie Barefoot Discovery Department Jackson Lirette Tim White Cagan Gurer Prachi Dhanania Estee Dilli Catalina Burbano Lisa Fleischer Christina Ioannidis Olivia P